LGALS3 and hepatocellular carcinoma: Silencing of galectin-3 can significantly reduce the mRNA and protein levels of urokinase-type plasminogen activator receptor (uPAR) and downstream signaling transduction pathway of uPARs in the HCC cells by inhibiting the MEK/ERK signaling pathway, further influencing the proliferation, migration, and invasion of the HCC cells (55).